Ana səhifə

Dr. Yen-Shen Lu Clinical Associate Professor


Yüklə 166.5 Kb.
tarix25.06.2016
ölçüsü166.5 Kb.
Dr. Yen-Shen Lu

Clinical Associate Professor, Department of Internal Medicine, National Taiwan University College of Medicine, Taiwan
Dr. Lu graduated from the Chinese Medical College of Medicine in 1992. He completed his postgraduate training in 2006 at the Institute of Clinical Medicine, National Taiwan University College of Medicine, Taiwan, and has been appointed as an Attending Doctor at the Department of Oncology, National Taiwan University Hospital since 1999. During 2005 to 2006, Dr. Lu had been a clinical fellow and post-doctoral researcher at the College of Pharmacy and Comprehensive Cancer Center at Ohio State University, USA.
Dr. Lu is a member of various societies, including Taiwan Society of Internal Medicine, American Association of Cancer Research (AACR), and the Breast Cancer Society of Taiwan. He was awarded scholarship in Training Award of 92th Annual Meeting of AACR in 2001. He is now appointed Clinical Associate Professor at the Department of Internal Medicine at the National Taiwan University College of Medicine.
Dr. Lu is an invited speaker in different international conferences, such as the Asia Oncology Summit and Global Breast Cancer Conference. He is a initiator, protocol writer, principal investigator and co-principal investigator for various clinical trials over the years. He has written over 30 conference papers and published over 60 journals in different international peer-reviewed journals, including Lancet Oncology and Cancer Research. Dr. Lu is also the co-author in a book chapter entitled ‘Histone Deacetylase Inhibitors in Cancer Therapy’.


CURRICULUM VIATE


Yen - Shen Lu, MD., PhD.

盧彥伸醫師

PERSONAL：




Address:

Department of Oncology

National Taiwan University Hospital

#7 Chung-Shan South Road,

Taipei, Taiwan, 100

Tel：886-2-23123456 ext 7009 Fax：886-2-23711174

e-mail：yslu@ntu.edu.tw






Date of Birth:

Nov 11, 1966




Place of Birth:

Taipei, Taiwan




Marital Status:

Married

EDUCATION：




M.D.

Chinese Medical College of Medicine 1985-1992




Ph.D.

Institute of Clinical Medicine, National Taiwan University College of Medicine 1998-2006

PROFESSIONAL TRAINING：




1991-1992

Internship：National Taiwan University College of Medicine




1993-1996

Residency：Department of Medicine, National Taiwan University Hospital




1996-1997

Chief Residency：Department of Oncology, National Taiwan University Hospital




1997-1999

2005-2006
Fellowship, Department of Oncology, National Taiwan University Hospital

Clinical fellow and Postdoctoral researcher, College of pharmacy, and Comprehensive Cancer Center, Ohio State University



HOSPITAL APPOINTMENTS：




1999-2001

2001-present
Attending doctor, Department of Oncology, En Chu Kong Hospital

Attending doctor, Department of Oncology, National Taiwan University Hospital

ACADEMIC APPOINTMENTS：










2007-2008

2008-present
Adjunct Associate Professor, Department of Internal Medicine, National Taiwan University College of Medicine

Clinical Associate Professor, Department of Internal Medicine, National Taiwan University College of Medicine



LICENSURE and CENTIFICATION：










Chinese Medical License #021928（1992）

Chinese Board of Internal Medicine #004509（1997）

Chinese Board of Medical Oncology #870003 (1998 )

Chinese Board of Mammary Medicine #0415 ( 2006 )






MEMBERSHIPS：







Taiwan Society of Internal Medicine

1996 – Present







The Chinese Oncology Society

1998 – Present







The Breast Cancer Society of Taiwan

2004 - Present







American Association of Cancer Research

2001-Present




Awards:

Scholar in Training Award of 92th Annual Meeting of AACR in 2001.



SCI PUBLICATIONS：






  1. Po-Han Lin; Chang-Fang Chiu; Yen-Shen Lu. Cisplatin as an active treatment in zoledronate-refractory hypercalcemia. Ann Oncol. 2011 Apr 2 [Epub ahead of print] PMID:21460375

  2. Lack of compensatory pAKT activation and eIF4E phosphorylation of lymphoma cells towards mTOR inhibitor, RAD001. Kuo SH, Hsu CH, Chen LT, Lu YS, Lin CH, Yeh PY, Jeng HJ, Gao M, Yeh KH, Cheng AL Eur J Cancer. 2011 Feb 17.

  3. The Association of Infrared Imaging Findings of the Breast with Hormone Receptor and Human Epidermal Growth Factor Receptor 2 Status of Breast Cancer. Wang J, Shih TT, Yen RF, Lu YS, Chen CY, Mao TL, Lin CH, Kuo WH, Tsai YS, Chang KJ, Chien KL. Acad Radiol. 2010 Dec 1

  4. Phase II study of docetaxel, capecitabine, and cisplatin as neoadjuvant chemotherapy for locally advanced breast cancer Yen-Shen Lu, Dar-Ren Chen, Ling-Min Tseng, Dah-Cherng Yeh, Shou-Tung Chen, Chia-Ming Hsieh, Hwei-Chung Wang, Hsien-Tang Yeh, Sung-Hsin Kuo, Chiun-Sheng Huang. Cancer Chemotherapy and Pharmacology. 2010 In press

  5. Combinations of mTORC1 inhibitor RAD001 with gemcitabine and paclitaxel for treating non-Hodgkin lymphoma Chun-Te Chiang, Pei-Yen Yeh, Ming Gao, Chun-Wei Chen, Ling-Chun Yeh, Wen-Chi Feng, Sung-Hsin Kuo, Chih-Hung Hsu, Yen-Shen Lu* and Ann-Lii Cheng, Cancer Letter, 2010, 2010 Dec 8;298(2):195-203. (*corresponding author)

  6. The prevalence and assessment of ErbB2-positive breast cancer in Asia: A literature survey. Yew Oo Tan, Sehwan Han, Yen-Shen Lu, Cheng-Har Yip, Patrapim Sunpaweravong, Joon Jeong, Priscilla B. Caguioa, Shyam Aggarwal, Ee Min Yeoh, BSc, and Hanlim Moon. Cancer, 2010 Dec 1;116(23):5348-57.

  7. Vinorelbine plus 24-hour infusion of high-dose 5-fluorouracil and leucovorin as effective palliative chemotherapy for breast cancer patients with acute disseminated intravascular coagulation, Po-Han Lin, Yen-Shen Lu, Ching-Hung Lin, Dwan-Ying Chang, Chiun-Shen Huang, Ann-Lii Cheng,Kun-Huei Yeh Anticancer Research 2010 Jul;30(7):3087-91.

  8. Management of ErbB2-positive breast cancer – insights from preclinical and clinical studies with lapatinib, Charles Vogel, Arlene Chan, Brunilde Gril, Sung-Bae Kim, Junichi Kurebayashi, Li Liu, Yen-Shen Lu, Hanlim Moon Jap. J Clin. Oncol. 2010 Nov;40(11):999-1013

  9. Predictive and Prognostic Values of Tau and ERCC1 in Advanced Breast Cancer Patients Treated with Paclitaxel and Cisplatin. Shao YY, Kuo KT, Hu FC, Lu YS, Huang CS, Liau JY, Lee WC, Hsu C, Kuo WH, Chang KJ, Lin CH, Cheng AL. Jpn J Clin Oncol. 2010 Apr;40(4):286-93

  10. Unique features of breast cancer in Asian women-Breast cancer in Taiwan as an example. Huang CS, Lin CH, Lu YS, Shen CY. J Steroid Biochem Mol Biol. 2010 Feb 28;118(4-5):300-3..

  11. Fractionated evaluation of immunohistochemical hormone receptor expression enhances prognostic prediction in breast cancer patients treated with tamoxifen as adjuvant therapy. Lin CH, Lien HC, Hu FC, Lu YS, Kuo SH, Wu LC, You SL, Cheng AL, Chang KJ, Huang CS. J Zhejiang Univ Sci B. 2010 Jan;11(1):1-9.

  12. Management of HER2-positive breast cancer in Asia: consensus statement from the Asian Oncology Summit. Nan Soon Wong, Benjamin O Anderson, Kei Siong Khoo, Peng Tiam Ang, Cheng Har Yip,Yen-Shen Lu, Narind Voravud, Zhi-Ming Shao, Kathleen I Pritchard. Lancet Oncol. 2009 Nov;10(11):1077-85.

  13. O(6)-Methylguanine-DNA methyltransferase expression and prognostic value in brain metastases of lung cancers. Wu PF, Kuo KT, Kuo LT, Lin YT, Lee WC, Lu YS, Yang CH, Wu RM, Tu YK, Tasi JC, Tseng HM, Tseng SH, Cheng AL, Lin CH. Lung Cancer. 2009 Sep 7

  14. Locoregional Therapy Improves Survival for Metastatic Breast Cancer Patients? Benefit Remains Questionable! Chang DY, Lin CH, Lu YS. J Clin Oncol. 2009 Nov 1;27(31):e179;

  15. Induction of Bim Expression Contributes to the Antitumor Synergy Between Sorafenib and Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase Inhibitor CI-1040 in Hepatocellular Carcinoma. Ou DL, Shen YC, Liang JD, Liou JY, Yu SL, Fan HH, Wang DS, Lu YS, Hsu C, Cheng AL. Clin Cancer Res. 2009 Sep 8. 15(18):5820-8.

  16. Molecular Subtypes of Breast Cancer Emerging in Young Women in Taiwan: Evidence for More than Just Westernization as a Reason for the Disease in Asia Ching-Hung Lin, Jau-Yu Liau, Yen-Shen Lu, Chiun-Sheng Huang, Wei-Chung Lee, Kuan-Ting Kuo, Ying-Chun Shen, Sung-Hsin Kuo, Chieh Lan, Jacqueline Ming Liu, Wun-Hon Kuo, King-Jen Chang, and Ann-Lii Cheng, Cancer Epidemiology, Biomarkers & Prevention. 2009 Jun;18(6):1807-14.

  17. Bortezomib overcomes TRAIL resistance in hepatocellular carcinoma cells in part through the inhibition of PI3K/Akt pathway Kuen-Feng Chen, Pei-Yen Yeh, Chiun Hsu , Chih-Hung Hsu, Yen-Shen Lu, Hsing-Pang Hsieh, Pei-Jer Chen, Ann-Lii Cheng. J. Biol Chem 2009 April 24;284(17):11121-33.

  18. OSU-03012, a novel celecoxib derivative, induces reactive oxygen species-related autophagy in hepatocellular carcinoma.Gao M, Yeh PY, Lu YS, Hsu CH, Chen KF, Lee WC, Feng WC, Chen CS, Kuo ML, Cheng AL. . Cancer Res 2008 Nov 15;68(22):9348-57.

  19. NF-kappaB p50 promotes tumor cell invasion through negative regulation of invasion suppressor gene CRMP-1 in human lung adenocarcinoma cells. Gao M, Yeh PY, Lu YS, Chang WC, Kuo ML, Cheng AL. Biochem Biophys Res Commun. 2008 Nov 14;376(2):283-7.

  20. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells. Chen KF, Yeh PY, Yeh KH, Lu YS, Huang SY, Cheng AL Cancer Res. 2008 Aug 15;68(16):6698-707.

  21. Dose variation and regimen modification of adjuvant chemotherapy in daily practice affect survival of stage I-II and operable stage III Taiwanese breast cancer patients. Kuo SH, Lien HC, You SL, Lu YS, Lin CH, Chen TZ, Huang CS, Breast. 2008 Dec;17(6):646-53. Epub 2008 Jul 1

  22. The CYP19 TTTA Repeat Polymorphism Is Related to the Prognosis of Premenopausal Stage I-II and Operable Stage III Breast Cancers, Huang CS, Kuo SH, Lien HC, Yang SY, You SL, Shen CY, Lin CH, Lu YS, Chang KJ. Oncologist. 2008;13:751-60.

  23. Differential expression of glucocorticoid receptor in carcinomas of the human digestive system, H-C Lien, Y-S Lu, C-T Shun, Y-T Yao, W-C Chang1 & A-L Cheng Histopathology 2008 Feb;46(4):1119-30

  24. FTY720 Induces Apoptosis in Hepatocellular Carcinoma Cells through Activation of Protein Kinase C Delta Signaling. Jui-Hsiang Hung, Yen-Shen Lu, Yu-Chieh Wang, Yi-Hui Ma, Da-Sheng Wang, Samuel K. Kulp, Natarajan Muthusamy, John C Byrd, Ann-Lii Cheng, and Ching-Shih Chen Cancer Research, 68:1204-1212, 2008.

  25. Efficacy of OSU-HDAC42, a Novel Histone Deacetylase Inhibitor, in Murine Models of Hepatocellular Carcinoma Yen-Shen Lu, Yoko Kashida, Samuel K. Kulp, Yu-Chieh Wang, Jui-Hsiang Hung, Monica Tang, Zhong-Zhe Lin, Te-Jung Chen, Ann-Lii Cheng, and Ching-Shih Chen. Hepatology, 2007 Oct;46(4):1119-30.

  26. Pneumatosis coli after etoposide chemotherapy for breast cancer. Shih IL, Lu YS, Wang HP, Liu KL. J Clin Oncol. 2007 Apr 20;25(12):1623-5.

  27. Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation. Chen CS, Wang YC, Yang HC, Huang PH, Kulp SK, Yang CC, Lu YS, Matsuyama S, Chen CY, Chen CS. Cancer Res. 2007 Jun 1;67(11):5318-27.

  28. A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer. Lin CC, Cheng AL, Hsu CH, Lu YS, Hsu C, Yeh KH, Wu CY, Huang CS, Yang CH. Anticancer Res. 2007 ;27(1B):641-5.

  29. Differential expression of glucocorticoid receptor in human breast tissues and related neoplasms. Lien HC, Lu YS, Cheng AL, Chang WC, Jeng YM, Kuo YH, Huang CS, Chang KJ, Yao YT. J Pathol. 2006 Jul;209(3):317-27.

  30. Glucocorticoid receptor expression in advanced non-small cell lung cancer: clinicopathological correlation and in vitro effect of glucocorticoid on cell growth and chemosensitivity Lu YS, Lien HC, Yeh PY, Kuo SH, Chang WC, Kuo ML, Cheng AL. Lung Cancer. 2006 Sep;53(3):303-10.

  31. Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer. Ch'ang HJ, Wang CC, Cheng AL, Hsu C, Lu YS, Chang MC, Lin JT, Wang HP, Shiah HS, Liu TW, Chang JY, Whang-Peng J, Chen LT. J Gastroenterol Hepatol. 2006 May;21(5):874-9.

  32. Glucocorticoids enhance cytotoxicity of cisplatin via suppression of NF-{kappa}B activation in the glucocorticoid receptor-rich human cervical carcinoma cell line SiHa. Lu YS, Yeh PY, Chuang SE, Gao M, Kuo ML, Cheng AL. J Endocrinol. 2006 Feb;188(2):311-9.

  33. Effects of glucocorticoids on the growth and chemosensitivity of carcinoma cells are heterogeneous and require high concentration of functional glucocorticoid receptors. Lu YS, Lien HC, Yeh PY, Yeh KH, Kuo ML, Kuo SH, Cheng AL. World J Gastroenterol. 2005 Oct 28;11(40):6373-80.

  34. Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patients. Su WP, Wen CC, Hsiung CA, Su IJ, Cheng AL, Chang MC, Tsao CJ, Kao WY, Uen WC, Hsu C, Hsu CH, Lu YS, Tien HF, Chao TY, Chen LT, Whang-Peng J, Chen PJ. World J Gastroenterol. 2005 Sep 14;11(34):5283-8.

  35. Phase II Study of Weekly Paclitaxel and 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin in the Treatment of Recurrent or Metastatic Gastric Cancer. Kun-Huei Yeh, Yen-Shen Lu, Chih-Hung Hsu, Jing-Fang Lin, Chiun Hsu, Sung-Hsin Kuo, Shiou-Jr Li, Ann-Lii Cheng. Oncology 2005 Oncology. 2005;69(1):88-95.

  36. Phase II Study of Weekly Vinorelbine and 24-hour Infusion of High-dose 5-Fluorouracil Plus Leucovorin as First-line Treatment of Advanced Breast Cancer KH Yeh, YS Lu, CH Hsu, JF Lin, HJ Chao, TC Huang, CY Chung, CS Chang, CH Yang, AL Cheng British Journal of Cancer . 2005 92:1013-1018

  37. Angiogenic response of locally advanced breast cancer to neoadjuvant chemotherapy evaluated with parametric histogram from dynamic contrast-enhanced MRI. Yeun-Chung Chang, Chiun-Sheng Huang, Yi-Jui Liu, Jyh-Horng Chen, Yen-Shen Lu, Wen-Yih I Tseng Phys. Med. Biol. 49 (2004)3593-3602 2004

  38. Phase II study of combination doxorubicin, interferon-alpha, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma. Lu YS. Hsu C. Li CC. Kuo SH. Yeh KH. Yang CH. Hsu CH. Wu CY. Cheng AL Hepato-Gastroenterology. 51(57):815-9, 2004

  39. Recent advances in the management of primary breast cancers. Lu YS, Kuo SH, Huang CS J Formos Med Assoc. 103(8):579-98.2004

  40. Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/leucovorin for locally advanced or metastatic carcinoma of the biliary tract. Hsu C. Shen YC. Yang CH. Yeh KH. Lu YS. Hsu CH. Liu HT. Li CC. Chen JS. Wu CY. Cheng AL British Journal of Cancer. 90(9):1715-9,2004

  41. High-dose tamoxifen modulates drug resistance to doxorubicin, dacarbazine and ifosfamide in metastatic uterine leiomyosarcoma. Yeh KH. Lu YS. Hsiao CH. Cheng AL. Anticancer Research. 23(6D):5133-7, 2003

  42. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-f;uorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer – improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil. CH Hsu, AL Cheng, C Hsu, CH Yang, YS Lu, CC Lin, CF Bu, KH Yeh. Anticancer Research. 22: 3621-28, 2002.

  43. Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naïve patients with locally advanced or metastatic breast cancer. C, Hsu, CS Huang, TY Chao, YS Lu. CF Bu, MM, Chen, AL Cheng. Cancer 95(10) 2044-50, 2002.

  44. Basal levels and patterns of anticancer drug-induced activation of NF-kB, and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells. S.E. Chung, P.Y. Yeh, Y.S. Lu, G.M. Lai, C.M. Liao, M. Gao, A.L. Cheng. Biochemical Pharmacology. 63(9):1709-16, 2002.

  45. Chen HS. Yen TS. Lu YS. Yang JC. Ko YL. Transient 'milky urine' after cardiac catheterization: another unreported cause of non-parasitic chyluria [letter]. Nephron. 72(2):367-8, 1996.


Conference paper：

  1. C. Hsu, Y.-C. Shen, C.-H. Yang, K.-H. Yeh, Y.-S. Lu, C.-C. Li, C.-Y. Wu, A.-L. Cheng Phase II study of weekly gemcitabine plus 24-hour infusion of high-dose 5-fluorouracil/leucovorin for locally advanced or metastatic carcinoma of the biliary tract Proc Am Soc Clin Oncol 22: 2003 (abstr 1322)

  2. K. H. Yeh, W. Lu, Y. F. Ho, Y. Lu, M. Y. Liu, R. R. Chen, A. L. Cheng A phase I and pharmacokinetic study of weekly 48-hour infusion of high-dose 5-fluorouracil and folinic acid in patients with recurrent/metastatic colorectal cancer 2004 Gastrointestinal Cancer Synposium abstract 261

  3. KH Yeh, YS Lu, CH Hsu, C Hsu, H J Chao, CH Hsiao, SH Kuo, JC Lin, CH Yang, AL Cheng A phase II study of weekly vinorelbine and 24-hour infusion of high-dose 5-fluorouracil/leucovorin (VNB-HDFL) in the first-line treatment of advanced breast cancer Proc Am Soc Clin Oncol 21: 2002 (abstr 2006)

  4. K. Yeh, C. Hsu, Y. Lu, C. Hsu, S. Kuo, C. Huang, Y. Shen, C. Hsiao, C. Yang, A. Cheng. Phase II study of sequential non-cross-resistant chemotherapy using weekly 24-hour infusion of cisplatin, high-dose 5-fluorouracil and leucovorin (P-HDFL) followed by weekly docetaxel and irinotecan (DI) for recurrent or metastatic gastric cancer: an interim analysis Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 14063

  5. K.-H. Yeh, C.-H. Hsu, J.-F. Lin, Y.-S. Lu, H.-T. Li, C.-L. Huang, C.-H. Hsiao, A.-L. Cheng. Prolonged survival in a pilot study of sequential non-cross-resistant chemotherapy using weekly 24-hour infusion of cisplatin, high-dose 5-fluorouracil and leucovorin (P-HDFL) followed by weekly docetaxel and irinotecan (DI) for recurrent or metastatic gastric cancer Proc Am Soc Clin Oncol 22: 2003 (abstr 1229)

  6. C.-H. Hsu, K.-H. Yeh, C.-C. Lin, Z.-Z. Lin, C. Hsu, Y.-S. Lu, C.-F. Bu, A.-L. Cheng. Multi-fractionation of paclitaxel and cisplatin by twice weekly schedule, plus weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin (twice weekly TP-HDFL) in the treatment of metastatic or recurrent esophageal cancer. Proc Am Soc Clin Oncol 22: 2003 (abstr 1336)

  7. Chih-Hung Hsu, Kun-Huei Yeh, Chiun Hsu, Chih-Hsin Yang, Yen-Shen Lu, Chia-Chi Lin, Ching-Fang Bu, Ann-Lii Cheng. Phase II Clinical Trial of Methotrexate, Cisplatin, and 24-Hour Infusion of High-Dose 5-Fluororuacil and Leucovorin (MP-HDFL) for the Treatment of Metastatic or Recurrent Esophageal Cancer Proc Am Soc Clin Oncol 20: 2001 (abstr 2299)

  8. Y. S. Lu, S. H. Kuo, W. P. Su, C. H. Yang, C. Hsu, T. L. Yang, C. S. Huang. A phase II trial of docetaxel, capecitabine, and cisplatin as neoadjuvant chemotherapy for locally advanced breast cancer. Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1 Supplement), 2005: 861

  9. Yen-Shen Lu, Pei-Yen Yeh, Ming Gao, Shuang-En Chuang, Ann-Lii Cheng: Glucocorticoids (GC) enhance p21 expression and induce G1 phase cell cycle arrest in MCF-7 cells - the possible role of GC receptors and their co-regulator. AACR Meeting Abstracts, Mar 2004; 2004: 100

  10. Yen-Shen Lu, Chiun-Sheng Huang: Phase II Trial Combining Weekly Doxetaxel with Tegafur/Uracil for Chemo- therapy-Naive Patients with Locally Advanced or Metastatic Breast Carcinoma. (2005/12) Poster Session

  11. Yen-Shen Lu, Pei-Yen Yeh, Sung-Hsin Kuo, Wen-Ching Chang, Ann-Lii Cheng.: Expression of glucocorticoids receptor in tumor tissue may affect the outcome of advanced non-small cell lung cancer patients who received chemotherapy and concurrent glucocorticoids treatment. AACR Meeting Abstracts, Apr 2005; 2005: 952 - 953.

  12. Yen-Shen Lu, Yoko Kashida, Jui-Hsiang Hung, Chang-Shi Chen, Yu-Chieh Wang, Ann-Lii Cheng, Ching-Shih Chen.: In Vivo Efficacy of OSU-HDAC42, a Novel Phenylbutyrate-based Histone Deacetylase Inhibitor, in Human Hepatocellular Carcinoma Animal Models. AACR Meeting Abstracts, Apr 2007; 2007: 705

  13. Yen-Shen Lu, Pei-Yen Yeh, Chih-Hung Hsu, Sung-Hsin Kuo, An-Chieh Lee, Ann-Lii Cheng, Differential regulation of cytokine expression determines the different drug sensitivity between carcinomas and lymphomas towards mTOR inhibitor AACR Meeting Abstracts, Apr 2008; 2008: 1478

  14. Chun-Te Chiang, Yen-Shen Lu, Pei-Yen Yeh, Ling-Chun Yeh, Chih-Hung Hsu, Sung-Hsin Kuo, Ann-Lii Cheng, RAD001 Sensitizes Gemcitabine- and Paclitaxel-induced Cytotoxicity in Non-Hodgkin's Lymphoma Cells AACR Meeting Abstracts, Apr 2009; 2009: 1837.

  15. Ming Gao, Pei-Yen Yeh, Ching-Hung Lin, Yen-Shen Lu, Min-Liang Kuo, and Ann-Lii Cheng NF-B p50-mediated down-regulation of CRMP-1 is involved in tumor cell invasiveness in human lung adenocarcinoma cells AACR Meeting Abstracts, Apr 2008; 2008: 4552.

  16. Y. Lu, L. Tseng, M. Hou, C. Lin, H. Li, S. Chen. Treatment patterns and clinical outcomes of patients with advanced breast cancer after failure of an anthracycline and a taxane in Taiwan. 2010 ASCO Annual Meeting J Clin Oncol 28, 2010 (suppl; abstr e11504)

  17. C. Lin, C. Huang, Y. Lu, J. Laiu, S. Huang, W. Kuo, W. Kuo, K. Chang, A. Cheng. Evaluation of estrogen receptor expression as a prognostic factor for very young women (below 35 years) with breast cancer in Taiwan J Clin Oncol 27, 2009 (suppl; abstr e22163)

  18. Y. Shen, C. Hsu, S. Kuo, Y. Lu, C. Lin, C. Huang, A. Cheng A phase II study of weekly low-dose paclitaxel plus 24-hour infusion of cisplatin as first-line chemotherapy for metastatic breast cancer (MBC) Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 1100

  19. Jason Chia-Hsien Cheng, Chia-Hung Chou, Yen-Shen Lu, Ipih Hana, Chan-Hsun Hsu, Ann-Lii Cheng, and Ching-Shih Chen Abstract #3963: Efficacy of combining a novel histone deacetylase inhibitor with radiotherapy in human hepatocellular carcinoma through inhibition of DNA repair AACR Meeting Abstracts, Apr 2009; 2009: 3963.

  20. Ming Gao, Pei Yen Yeh, Yen-Shen Lu, Hsiu-Mei Lin, and Ann-Lii Cheng
    Abstract #4208: EGFR variant 4 complexes with NF-κB p50 to upregulate VEGF receptor 2 expression in lung cancer cells. AACR Meeting Abstracts, Apr 2009; 2009: 4208.

  21. Y.H. Kuo, C.H. Lin, W.Y. Shau, T.J. Chen, S.H. Yang, S.M. Huang, A.L. Cheng, Y.S. Lu, DYNAMICS OF CIRCULATING ENDOTHELIAL CELLS AND ENDOTHELIAL PROGENITOR CELLS IN BREAST CANCER PATIENTS RECEIVING CYTOTOXIC CHEMOTHERAPY. Ann Oncol (2010) 21(suppl 8): viii78-viii95

Book：

1. Arrong Sargen, Yen-Shen Lu, Ann-Lii Cheng, Ching-Shih Cheng. Chapter 12; Histone Deacetylase Inhibitors in Cancer Therapy; Cancer Epigenetics ed 1. Taylor & Francis , 2008,


CURRICULUM VIATE


Yen - Shen Lu, MD., PhD.

盧彥伸醫師

PERSONAL：




Address:

Department of Oncology

National Taiwan University Hospital

#7 Chung-Shan South Road,

Taipei, Taiwan, 100

Tel：886-2-23123456 ext 7009 Fax：886-2-23711174

e-mail：yslu@ntu.edu.tw






Date of Birth:

Nov 11, 1966




Place of Birth:

Taipei, Taiwan




Marital Status:

Married

EDUCATION：




M.D.

Chinese Medical College of Medicine 1985-1992




Ph.D.

Institute of Clinical Medicine, National Taiwan University College of Medicine 1998-2006

PROFESSIONAL TRAINING：




1991-1992

Internship：National Taiwan University College of Medicine




1993-1996

Residency：Department of Medicine, National Taiwan University Hospital




1996-1997

Chief Residency：Department of Oncology, National Taiwan University Hospital




1997-1999

2005-2006
Fellowship, Department of Oncology, National Taiwan University Hospital

Clinical fellow and Postdoctoral researcher, College of pharmacy, and Comprehensive Cancer Center, Ohio State University



HOSPITAL APPOINTMENTS：




1999-2001

2001-present
Attending doctor, Department of Oncology, En Chu Kong Hospital

Attending doctor, Department of Oncology, National Taiwan University Hospital

ACADEMIC APPOINTMENTS：










2007-2008

2008-present
Adjunct Associate Professor, Department of Internal Medicine, National Taiwan University College of Medicine

Clinical Associate Professor, Department of Internal Medicine, National Taiwan University College of Medicine



LICENSURE and CENTIFICATION：










Chinese Medical License #021928（1992）

Chinese Board of Internal Medicine #004509（1997）

Chinese Board of Medical Oncology #870003 (1998 )

Chinese Board of Mammary Medicine #0415 ( 2006 )






MEMBERSHIPS：







Taiwan Society of Internal Medicine

1996 – Present







The Chinese Oncology Society

1998 – Present







The Breast Cancer Society of Taiwan

2004 - Present







American Association of Cancer Research

2001-Present




Awards:

Scholar in Training Award of 92th Annual Meeting of AACR in 2001.



SCI PUBLICATIONS：






  1. Po-Han Lin; Chang-Fang Chiu; Yen-Shen Lu. Cisplatin as an active treatment in zoledronate-refractory hypercalcemia. Ann Oncol. 2011 Apr 2 [Epub ahead of print] PMID:21460375

  2. Lack of compensatory pAKT activation and eIF4E phosphorylation of lymphoma cells towards mTOR inhibitor, RAD001. Kuo SH, Hsu CH, Chen LT, Lu YS, Lin CH, Yeh PY, Jeng HJ, Gao M, Yeh KH, Cheng AL Eur J Cancer. 2011 Feb 17.

  3. The Association of Infrared Imaging Findings of the Breast with Hormone Receptor and Human Epidermal Growth Factor Receptor 2 Status of Breast Cancer. Wang J, Shih TT, Yen RF, Lu YS, Chen CY, Mao TL, Lin CH, Kuo WH, Tsai YS, Chang KJ, Chien KL. Acad Radiol. 2010 Dec 1

  4. Phase II study of docetaxel, capecitabine, and cisplatin as neoadjuvant chemotherapy for locally advanced breast cancer Yen-Shen Lu, Dar-Ren Chen, Ling-Min Tseng, Dah-Cherng Yeh, Shou-Tung Chen, Chia-Ming Hsieh, Hwei-Chung Wang, Hsien-Tang Yeh, Sung-Hsin Kuo, Chiun-Sheng Huang. Cancer Chemotherapy and Pharmacology. 2010 In press

  5. Combinations of mTORC1 inhibitor RAD001 with gemcitabine and paclitaxel for treating non-Hodgkin lymphoma Chun-Te Chiang, Pei-Yen Yeh, Ming Gao, Chun-Wei Chen, Ling-Chun Yeh, Wen-Chi Feng, Sung-Hsin Kuo, Chih-Hung Hsu, Yen-Shen Lu* and Ann-Lii Cheng, Cancer Letter, 2010, 2010 Dec 8;298(2):195-203. (*corresponding author)

  6. The prevalence and assessment of ErbB2-positive breast cancer in Asia: A literature survey. Yew Oo Tan, Sehwan Han, Yen-Shen Lu, Cheng-Har Yip, Patrapim Sunpaweravong, Joon Jeong, Priscilla B. Caguioa, Shyam Aggarwal, Ee Min Yeoh, BSc, and Hanlim Moon. Cancer, 2010 Dec 1;116(23):5348-57.

  7. Vinorelbine plus 24-hour infusion of high-dose 5-fluorouracil and leucovorin as effective palliative chemotherapy for breast cancer patients with acute disseminated intravascular coagulation, Po-Han Lin, Yen-Shen Lu, Ching-Hung Lin, Dwan-Ying Chang, Chiun-Shen Huang, Ann-Lii Cheng,Kun-Huei Yeh Anticancer Research 2010 Jul;30(7):3087-91.

  8. Management of ErbB2-positive breast cancer – insights from preclinical and clinical studies with lapatinib, Charles Vogel, Arlene Chan, Brunilde Gril, Sung-Bae Kim, Junichi Kurebayashi, Li Liu, Yen-Shen Lu, Hanlim Moon Jap. J Clin. Oncol. 2010 Nov;40(11):999-1013

  9. Predictive and Prognostic Values of Tau and ERCC1 in Advanced Breast Cancer Patients Treated with Paclitaxel and Cisplatin. Shao YY, Kuo KT, Hu FC, Lu YS, Huang CS, Liau JY, Lee WC, Hsu C, Kuo WH, Chang KJ, Lin CH, Cheng AL. Jpn J Clin Oncol. 2010 Apr;40(4):286-93

  10. Unique features of breast cancer in Asian women-Breast cancer in Taiwan as an example. Huang CS, Lin CH, Lu YS, Shen CY. J Steroid Biochem Mol Biol. 2010 Feb 28;118(4-5):300-3..

  11. Fractionated evaluation of immunohistochemical hormone receptor expression enhances prognostic prediction in breast cancer patients treated with tamoxifen as adjuvant therapy. Lin CH, Lien HC, Hu FC, Lu YS, Kuo SH, Wu LC, You SL, Cheng AL, Chang KJ, Huang CS. J Zhejiang Univ Sci B. 2010 Jan;11(1):1-9.

  12. Management of HER2-positive breast cancer in Asia: consensus statement from the Asian Oncology Summit. Nan Soon Wong, Benjamin O Anderson, Kei Siong Khoo, Peng Tiam Ang, Cheng Har Yip,Yen-Shen Lu, Narind Voravud, Zhi-Ming Shao, Kathleen I Pritchard. Lancet Oncol. 2009 Nov;10(11):1077-85.

  13. O(6)-Methylguanine-DNA methyltransferase expression and prognostic value in brain metastases of lung cancers. Wu PF, Kuo KT, Kuo LT, Lin YT, Lee WC, Lu YS, Yang CH, Wu RM, Tu YK, Tasi JC, Tseng HM, Tseng SH, Cheng AL, Lin CH. Lung Cancer. 2009 Sep 7

  14. Locoregional Therapy Improves Survival for Metastatic Breast Cancer Patients? Benefit Remains Questionable! Chang DY, Lin CH, Lu YS. J Clin Oncol. 2009 Nov 1;27(31):e179;

  15. Induction of Bim Expression Contributes to the Antitumor Synergy Between Sorafenib and Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase Inhibitor CI-1040 in Hepatocellular Carcinoma. Ou DL, Shen YC, Liang JD, Liou JY, Yu SL, Fan HH, Wang DS, Lu YS, Hsu C, Cheng AL. Clin Cancer Res. 2009 Sep 8. 15(18):5820-8.

  16. Molecular Subtypes of Breast Cancer Emerging in Young Women in Taiwan: Evidence for More than Just Westernization as a Reason for the Disease in Asia Ching-Hung Lin, Jau-Yu Liau, Yen-Shen Lu, Chiun-Sheng Huang, Wei-Chung Lee, Kuan-Ting Kuo, Ying-Chun Shen, Sung-Hsin Kuo, Chieh Lan, Jacqueline Ming Liu, Wun-Hon Kuo, King-Jen Chang, and Ann-Lii Cheng, Cancer Epidemiology, Biomarkers & Prevention. 2009 Jun;18(6):1807-14.

  17. Bortezomib overcomes TRAIL resistance in hepatocellular carcinoma cells in part through the inhibition of PI3K/Akt pathway Kuen-Feng Chen, Pei-Yen Yeh, Chiun Hsu , Chih-Hung Hsu, Yen-Shen Lu, Hsing-Pang Hsieh, Pei-Jer Chen, Ann-Lii Cheng. J. Biol Chem 2009 April 24;284(17):11121-33.

  18. OSU-03012, a novel celecoxib derivative, induces reactive oxygen species-related autophagy in hepatocellular carcinoma.Gao M, Yeh PY, Lu YS, Hsu CH, Chen KF, Lee WC, Feng WC, Chen CS, Kuo ML, Cheng AL. . Cancer Res 2008 Nov 15;68(22):9348-57.

  19. NF-kappaB p50 promotes tumor cell invasion through negative regulation of invasion suppressor gene CRMP-1 in human lung adenocarcinoma cells. Gao M, Yeh PY, Lu YS, Chang WC, Kuo ML, Cheng AL. Biochem Biophys Res Commun. 2008 Nov 14;376(2):283-7.

  20. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells. Chen KF, Yeh PY, Yeh KH, Lu YS, Huang SY, Cheng AL Cancer Res. 2008 Aug 15;68(16):6698-707.

  21. Dose variation and regimen modification of adjuvant chemotherapy in daily practice affect survival of stage I-II and operable stage III Taiwanese breast cancer patients. Kuo SH, Lien HC, You SL, Lu YS, Lin CH, Chen TZ, Huang CS, Breast. 2008 Dec;17(6):646-53. Epub 2008 Jul 1

  22. The CYP19 TTTA Repeat Polymorphism Is Related to the Prognosis of Premenopausal Stage I-II and Operable Stage III Breast Cancers, Huang CS, Kuo SH, Lien HC, Yang SY, You SL, Shen CY, Lin CH, Lu YS, Chang KJ. Oncologist. 2008;13:751-60.

  23. Differential expression of glucocorticoid receptor in carcinomas of the human digestive system, H-C Lien, Y-S Lu, C-T Shun, Y-T Yao, W-C Chang1 & A-L Cheng Histopathology 2008 Feb;46(4):1119-30

  24. FTY720 Induces Apoptosis in Hepatocellular Carcinoma Cells through Activation of Protein Kinase C Delta Signaling. Jui-Hsiang Hung, Yen-Shen Lu, Yu-Chieh Wang, Yi-Hui Ma, Da-Sheng Wang, Samuel K. Kulp, Natarajan Muthusamy, John C Byrd, Ann-Lii Cheng, and Ching-Shih Chen Cancer Research, 68:1204-1212, 2008.

  25. Efficacy of OSU-HDAC42, a Novel Histone Deacetylase Inhibitor, in Murine Models of Hepatocellular Carcinoma Yen-Shen Lu, Yoko Kashida, Samuel K. Kulp, Yu-Chieh Wang, Jui-Hsiang Hung, Monica Tang, Zhong-Zhe Lin, Te-Jung Chen, Ann-Lii Cheng, and Ching-Shih Chen. Hepatology, 2007 Oct;46(4):1119-30.

  26. Pneumatosis coli after etoposide chemotherapy for breast cancer. Shih IL, Lu YS, Wang HP, Liu KL. J Clin Oncol. 2007 Apr 20;25(12):1623-5.

  27. Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation. Chen CS, Wang YC, Yang HC, Huang PH, Kulp SK, Yang CC, Lu YS, Matsuyama S, Chen CY, Chen CS. Cancer Res. 2007 Jun 1;67(11):5318-27.

  28. A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer. Lin CC, Cheng AL, Hsu CH, Lu YS, Hsu C, Yeh KH, Wu CY, Huang CS, Yang CH. Anticancer Res. 2007 ;27(1B):641-5.

  29. Differential expression of glucocorticoid receptor in human breast tissues and related neoplasms. Lien HC, Lu YS, Cheng AL, Chang WC, Jeng YM, Kuo YH, Huang CS, Chang KJ, Yao YT. J Pathol. 2006 Jul;209(3):317-27.

  30. Glucocorticoid receptor expression in advanced non-small cell lung cancer: clinicopathological correlation and in vitro effect of glucocorticoid on cell growth and chemosensitivity Lu YS, Lien HC, Yeh PY, Kuo SH, Chang WC, Kuo ML, Cheng AL. Lung Cancer. 2006 Sep;53(3):303-10.

  31. Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer. Ch'ang HJ, Wang CC, Cheng AL, Hsu C, Lu YS, Chang MC, Lin JT, Wang HP, Shiah HS, Liu TW, Chang JY, Whang-Peng J, Chen LT. J Gastroenterol Hepatol. 2006 May;21(5):874-9.

  32. Glucocorticoids enhance cytotoxicity of cisplatin via suppression of NF-{kappa}B activation in the glucocorticoid receptor-rich human cervical carcinoma cell line SiHa. Lu YS, Yeh PY, Chuang SE, Gao M, Kuo ML, Cheng AL. J Endocrinol. 2006 Feb;188(2):311-9.

  33. Effects of glucocorticoids on the growth and chemosensitivity of carcinoma cells are heterogeneous and require high concentration of functional glucocorticoid receptors. Lu YS, Lien HC, Yeh PY, Yeh KH, Kuo ML, Kuo SH, Cheng AL. World J Gastroenterol. 2005 Oct 28;11(40):6373-80.

  34. Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patients. Su WP, Wen CC, Hsiung CA, Su IJ, Cheng AL, Chang MC, Tsao CJ, Kao WY, Uen WC, Hsu C, Hsu CH, Lu YS, Tien HF, Chao TY, Chen LT, Whang-Peng J, Chen PJ. World J Gastroenterol. 2005 Sep 14;11(34):5283-8.

  35. Phase II Study of Weekly Paclitaxel and 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin in the Treatment of Recurrent or Metastatic Gastric Cancer. Kun-Huei Yeh, Yen-Shen Lu, Chih-Hung Hsu, Jing-Fang Lin, Chiun Hsu, Sung-Hsin Kuo, Shiou-Jr Li, Ann-Lii Cheng. Oncology 2005 Oncology. 2005;69(1):88-95.

  36. Phase II Study of Weekly Vinorelbine and 24-hour Infusion of High-dose 5-Fluorouracil Plus Leucovorin as First-line Treatment of Advanced Breast Cancer KH Yeh, YS Lu, CH Hsu, JF Lin, HJ Chao, TC Huang, CY Chung, CS Chang, CH Yang, AL Cheng British Journal of Cancer . 2005 92:1013-1018

  37. Angiogenic response of locally advanced breast cancer to neoadjuvant chemotherapy evaluated with parametric histogram from dynamic contrast-enhanced MRI. Yeun-Chung Chang, Chiun-Sheng Huang, Yi-Jui Liu, Jyh-Horng Chen, Yen-Shen Lu, Wen-Yih I Tseng Phys. Med. Biol. 49 (2004)3593-3602 2004

  38. Phase II study of combination doxorubicin, interferon-alpha, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma. Lu YS. Hsu C. Li CC. Kuo SH. Yeh KH. Yang CH. Hsu CH. Wu CY. Cheng AL Hepato-Gastroenterology. 51(57):815-9, 2004

  39. Recent advances in the management of primary breast cancers. Lu YS, Kuo SH, Huang CS J Formos Med Assoc. 103(8):579-98.2004

  40. Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/leucovorin for locally advanced or metastatic carcinoma of the biliary tract. Hsu C. Shen YC. Yang CH. Yeh KH. Lu YS. Hsu CH. Liu HT. Li CC. Chen JS. Wu CY. Cheng AL British Journal of Cancer. 90(9):1715-9,2004

  41. High-dose tamoxifen modulates drug resistance to doxorubicin, dacarbazine and ifosfamide in metastatic uterine leiomyosarcoma. Yeh KH. Lu YS. Hsiao CH. Cheng AL. Anticancer Research. 23(6D):5133-7, 2003

  42. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-f;uorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer – improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil. CH Hsu, AL Cheng, C Hsu, CH Yang, YS Lu, CC Lin, CF Bu, KH Yeh. Anticancer Research. 22: 3621-28, 2002.

  43. Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naïve patients with locally advanced or metastatic breast cancer. C, Hsu, CS Huang, TY Chao, YS Lu. CF Bu, MM, Chen, AL Cheng. Cancer 95(10) 2044-50, 2002.

  44. Basal levels and patterns of anticancer drug-induced activation of NF-kB, and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells. S.E. Chung, P.Y. Yeh, Y.S. Lu, G.M. Lai, C.M. Liao, M. Gao, A.L. Cheng. Biochemical Pharmacology. 63(9):1709-16, 2002.

  45. Chen HS. Yen TS. Lu YS. Yang JC. Ko YL. Transient 'milky urine' after cardiac catheterization: another unreported cause of non-parasitic chyluria [letter]. Nephron. 72(2):367-8, 1996.


Conference paper：

  1. C. Hsu, Y.-C. Shen, C.-H. Yang, K.-H. Yeh, Y.-S. Lu, C.-C. Li, C.-Y. Wu, A.-L. Cheng Phase II study of weekly gemcitabine plus 24-hour infusion of high-dose 5-fluorouracil/leucovorin for locally advanced or metastatic carcinoma of the biliary tract Proc Am Soc Clin Oncol 22: 2003 (abstr 1322)

  2. K. H. Yeh, W. Lu, Y. F. Ho, Y. Lu, M. Y. Liu, R. R. Chen, A. L. Cheng A phase I and pharmacokinetic study of weekly 48-hour infusion of high-dose 5-fluorouracil and folinic acid in patients with recurrent/metastatic colorectal cancer 2004 Gastrointestinal Cancer Synposium abstract 261

  3. KH Yeh, YS Lu, CH Hsu, C Hsu, H J Chao, CH Hsiao, SH Kuo, JC Lin, CH Yang, AL Cheng A phase II study of weekly vinorelbine and 24-hour infusion of high-dose 5-fluorouracil/leucovorin (VNB-HDFL) in the first-line treatment of advanced breast cancer Proc Am Soc Clin Oncol 21: 2002 (abstr 2006)

  4. K. Yeh, C. Hsu, Y. Lu, C. Hsu, S. Kuo, C. Huang, Y. Shen, C. Hsiao, C. Yang, A. Cheng. Phase II study of sequential non-cross-resistant chemotherapy using weekly 24-hour infusion of cisplatin, high-dose 5-fluorouracil and leucovorin (P-HDFL) followed by weekly docetaxel and irinotecan (DI) for recurrent or metastatic gastric cancer: an interim analysis Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 14063

  5. K.-H. Yeh, C.-H. Hsu, J.-F. Lin, Y.-S. Lu, H.-T. Li, C.-L. Huang, C.-H. Hsiao, A.-L. Cheng. Prolonged survival in a pilot study of sequential non-cross-resistant chemotherapy using weekly 24-hour infusion of cisplatin, high-dose 5-fluorouracil and leucovorin (P-HDFL) followed by weekly docetaxel and irinotecan (DI) for recurrent or metastatic gastric cancer Proc Am Soc Clin Oncol 22: 2003 (abstr 1229)

  6. C.-H. Hsu, K.-H. Yeh, C.-C. Lin, Z.-Z. Lin, C. Hsu, Y.-S. Lu, C.-F. Bu, A.-L. Cheng. Multi-fractionation of paclitaxel and cisplatin by twice weekly schedule, plus weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin (twice weekly TP-HDFL) in the treatment of metastatic or recurrent esophageal cancer. Proc Am Soc Clin Oncol 22: 2003 (abstr 1336)

  7. Chih-Hung Hsu, Kun-Huei Yeh, Chiun Hsu, Chih-Hsin Yang, Yen-Shen Lu, Chia-Chi Lin, Ching-Fang Bu, Ann-Lii Cheng. Phase II Clinical Trial of Methotrexate, Cisplatin, and 24-Hour Infusion of High-Dose 5-Fluororuacil and Leucovorin (MP-HDFL) for the Treatment of Metastatic or Recurrent Esophageal Cancer Proc Am Soc Clin Oncol 20: 2001 (abstr 2299)

  8. Y. S. Lu, S. H. Kuo, W. P. Su, C. H. Yang, C. Hsu, T. L. Yang, C. S. Huang. A phase II trial of docetaxel, capecitabine, and cisplatin as neoadjuvant chemotherapy for locally advanced breast cancer. Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1 Supplement), 2005: 861

  9. Yen-Shen Lu, Pei-Yen Yeh, Ming Gao, Shuang-En Chuang, Ann-Lii Cheng: Glucocorticoids (GC) enhance p21 expression and induce G1 phase cell cycle arrest in MCF-7 cells - the possible role of GC receptors and their co-regulator. AACR Meeting Abstracts, Mar 2004; 2004: 100

  10. Yen-Shen Lu, Chiun-Sheng Huang: Phase II Trial Combining Weekly Doxetaxel with Tegafur/Uracil for Chemo- therapy-Naive Patients with Locally Advanced or Metastatic Breast Carcinoma. (2005/12) Poster Session

  11. Yen-Shen Lu, Pei-Yen Yeh, Sung-Hsin Kuo, Wen-Ching Chang, Ann-Lii Cheng.: Expression of glucocorticoids receptor in tumor tissue may affect the outcome of advanced non-small cell lung cancer patients who received chemotherapy and concurrent glucocorticoids treatment. AACR Meeting Abstracts, Apr 2005; 2005: 952 - 953.

  12. Yen-Shen Lu, Yoko Kashida, Jui-Hsiang Hung, Chang-Shi Chen, Yu-Chieh Wang, Ann-Lii Cheng, Ching-Shih Chen.: In Vivo Efficacy of OSU-HDAC42, a Novel Phenylbutyrate-based Histone Deacetylase Inhibitor, in Human Hepatocellular Carcinoma Animal Models. AACR Meeting Abstracts, Apr 2007; 2007: 705

  13. Yen-Shen Lu, Pei-Yen Yeh, Chih-Hung Hsu, Sung-Hsin Kuo, An-Chieh Lee, Ann-Lii Cheng, Differential regulation of cytokine expression determines the different drug sensitivity between carcinomas and lymphomas towards mTOR inhibitor AACR Meeting Abstracts, Apr 2008; 2008: 1478

  14. Chun-Te Chiang, Yen-Shen Lu, Pei-Yen Yeh, Ling-Chun Yeh, Chih-Hung Hsu, Sung-Hsin Kuo, Ann-Lii Cheng, RAD001 Sensitizes Gemcitabine- and Paclitaxel-induced Cytotoxicity in Non-Hodgkin's Lymphoma Cells AACR Meeting Abstracts, Apr 2009; 2009: 1837.

  15. Ming Gao, Pei-Yen Yeh, Ching-Hung Lin, Yen-Shen Lu, Min-Liang Kuo, and Ann-Lii Cheng NF-B p50-mediated down-regulation of CRMP-1 is involved in tumor cell invasiveness in human lung adenocarcinoma cells AACR Meeting Abstracts, Apr 2008; 2008: 4552.

  16. Y. Lu, L. Tseng, M. Hou, C. Lin, H. Li, S. Chen. Treatment patterns and clinical outcomes of patients with advanced breast cancer after failure of an anthracycline and a taxane in Taiwan. 2010 ASCO Annual Meeting J Clin Oncol 28, 2010 (suppl; abstr e11504)

  17. C. Lin, C. Huang, Y. Lu, J. Laiu, S. Huang, W. Kuo, W. Kuo, K. Chang, A. Cheng. Evaluation of estrogen receptor expression as a prognostic factor for very young women (below 35 years) with breast cancer in Taiwan J Clin Oncol 27, 2009 (suppl; abstr e22163)

  18. Y. Shen, C. Hsu, S. Kuo, Y. Lu, C. Lin, C. Huang, A. Cheng A phase II study of weekly low-dose paclitaxel plus 24-hour infusion of cisplatin as first-line chemotherapy for metastatic breast cancer (MBC) Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 1100

  19. Jason Chia-Hsien Cheng, Chia-Hung Chou, Yen-Shen Lu, Ipih Hana, Chan-Hsun Hsu, Ann-Lii Cheng, and Ching-Shih Chen Abstract #3963: Efficacy of combining a novel histone deacetylase inhibitor with radiotherapy in human hepatocellular carcinoma through inhibition of DNA repair AACR Meeting Abstracts, Apr 2009; 2009: 3963.

  20. Ming Gao, Pei Yen Yeh, Yen-Shen Lu, Hsiu-Mei Lin, and Ann-Lii Cheng
    Abstract #4208: EGFR variant 4 complexes with NF-κB p50 to upregulate VEGF receptor 2 expression in lung cancer cells. AACR Meeting Abstracts, Apr 2009; 2009: 4208.

  21. Y.H. Kuo, C.H. Lin, W.Y. Shau, T.J. Chen, S.H. Yang, S.M. Huang, A.L. Cheng, Y.S. Lu, DYNAMICS OF CIRCULATING ENDOTHELIAL CELLS AND ENDOTHELIAL PROGENITOR CELLS IN BREAST CANCER PATIENTS RECEIVING CYTOTOXIC CHEMOTHERAPY. Ann Oncol (2010) 21(suppl 8): viii78-viii95

Book：

1. Arrong Sargen, Yen-Shen Lu, Ann-Lii Cheng, Ching-Shih Cheng. Chapter 12; Histone Deacetylase Inhibitors in Cancer Therapy; Cancer Epigenetics ed 1. Taylor & Francis , 2008,

Verilənlər bazası müəlliflik hüququ ilə müdafiə olunur ©atelim.com 2016
rəhbərliyinə müraciət